pharmaphorum September 13, 2021
After some years of stagnant funding and growth France is now at an inflection point for health care innovation, says Jeito Capital’s Dr Rafaèle Tordjman.
Prior to the pandemic, our homegrown entrepreneurs felt too often they had to go abroad to the United States to get the funding they needed, government support for clinical trials and an ecosystem of fellow entrepreneurs to innovate with.
Our response to COVID-19 has shown we can break down barriers to rapidly get medicines to people and has emphasised the urgent need to finance and support biotech and biopharma companies.
To sustain that momentum, France has doubled down on its commitment to fostering innovation here, with the ambition of becoming a leader in Europe by...
Today's Sponsors
Today's Sponsor